CBLB 612

Drug Profile

CBLB 612

Alternative Names: CBLB-612

Latest Information Update: 28 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cleveland BioLabs
  • Class Chemoprotectants; Proteins
  • Mechanism of Action Haematopoietic system modulators; Stem cell modulators; Toll like receptor 2 agonists; Toll like receptor 6 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Stem cell mobilisation

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 19 Jul 2016 Cleveland BioLabs completes its phase II trial for Stem cell mobilisation (Treatment experienced, Prevention) in Russia (NCT02778763)
  • 16 May 2016 Cleveland BioLabs completes enrolment in its phase II trial for Stem cell mobilisation (Treatment experienced, Prevention) in Russia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top